Results 261 to 270 of about 103,961 (275)

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer

New England Journal of Medicine, 2022
Patrick Forde, Jonathan D Spicer, Shun Lu   +2 more
exaly  

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

Lancet, The, 2017
Anthony B El-Khoueiry, Bruno Sangro, Thomas Yau   +2 more
exaly  

Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab

Cell, 2017
Nadeem Riaz, Jonathan J Havel, Vladimir Makarov   +2 more
exaly  

Ipilimumab/nivolumab/Nivolumab/Nivolumab/relatlimab

Reactions Weekly
openaire   +1 more source

Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Lancet, The, 2017
Yoon-Koo Kang, Narikazu Boku, Taroh Satoh   +2 more
exaly  

An update on the immune landscape in lung and head and neck cancers

Ca-A Cancer Journal for Clinicians, 2020
Jennifer W Carlisle, Conor Steuer, Taofeek Kunle Owonikoko   +2 more
exaly  

Neoadjuvant ipilimumab–nivolumab superior to adjuvant nivolumab

Nature Reviews Clinical Oncology
openaire   +2 more sources

Nivolumab

Reactions Weekly, 2019
  +4 more sources

Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer

Cancer Cell, 2018
Matthew D Hellmann, Mark Awad, Emiliano Calvo   +2 more
exaly  

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

New England Journal of Medicine, 2018
Robert J Motzer, Nizar M Tannir, David F Mcdermott   +2 more
exaly